Thank you!

Your email has been successfully added to our mailing list.

×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
No thanks

CAPR – capricor therapeutics, inc. (US:NASDAQ)

DELAYED
$
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CAPR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/14
08:42 am
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low Report
Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Report
12/15
09:03 am
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at B. Riley.
Low Report
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at B. Riley.
Report
12/15
09:03 am
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at B. Riley.
Low Report
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at B. Riley.
Report
12/8
08:51 am
capr
Rating for CAPR
Medium Report
Rating for CAPR
Report
12/8
08:51 am
capr
Rating for CAPR
Medium Report
Rating for CAPR
Report
12/8
08:13 am
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium Report
Capricor Therapeutics (NASDAQ:CAPR) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Report
12/4
02:51 pm
capr
Rating for CAPR
Low Report
Rating for CAPR
Report
11/12
12:42 pm
capr
Rating for CAPR
Medium Report
Rating for CAPR
Report
11/12
12:42 pm
capr
Rating for CAPR
Medium Report
Rating for CAPR
Report
11/11
06:02 pm
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at Roth Capital.
Medium Report
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at Roth Capital.
Report
11/11
06:02 pm
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at Roth Capital.
Medium Report
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at Roth Capital.
Report
Latest Posts

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day
Information

Information

Support

Support

Contact us

Contact us

11201 N Tatum Blvd
Suite 300-79795
Phoenix, AZ 85028
info@newsquantified.com

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

11201 N Tatum Blvd
Suite 300-79795
Phoenix, AZ 85028
info@newsquantified.com
Stay in the know news, product updates and promotions.
Copyright Ⓒ News Quanitifed LLC 2012-2026, All product trademarks, names, logos, and brands are property of their respective owners. Image(s) or Footage (as applicable), used under license from Shutterstock.com. 3.0.0